NIA Launches Research Centers to Advance Drug Discovery in Alzheimer’s

NIA Launches Research Centers to Advance Drug Discovery in Alzheimer’s
To advance the pipeline for innovative therapeutics in Alzheimer’s (AD), the National Institute on Aging (NIA) will invest an expected $73 million over five years in two new translational research centers. The centers will be funded through the NIA’s Alzheimer Centers for the Discovery of New Medicines program, and offer more infrastructure for the development of top-shelf investigative tools and technologies necessary for the validation and advancement of new therapy targets. Translational research is specifically designed to improve health outcomes. Using an open-access platform, the centers will share with the wider research community, for free, their data, methodologies and experimental and computational tools for use in drug discovery and in efforts to enhance disease understanding.  The NIA’s Accelerating Medicines Partnership-Alzheimer’s Disease program (AMP-AD), which has yielded 500 prospective AD targets, will serve as the centers’ foundation. “Through these centers, NIH will expand the use of open science and open source principles to de-risk novel drug targets, with the goal of facilitating the development of new treatments for Alzheimer’s,” Francis S. Collins, MD, PhD,
Subscribe or to access all post and page content.